Human CD79A ELISA Kit (V2LY-0626-LY5601)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.01 ng/mL
Detection Range
0.02-3.8 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
25.0 kDa
Components
  • Pre-coated ELISA plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
CD79a Molecule
Function
Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B-cells.
Biological Process
Adaptive immune response Source: UniProtKB-KW
B cell activation Source: UniProtKB
B cell differentiation Source: UniProtKB
B cell proliferation Source: UniProtKB
B cell receptor signaling pathway Source: UniProtKB
Cellular Location
Cell membrane. Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts.
Involvement in disease
Agammaglobulinemia 3, autosomal recessive (AGM3): The disease is caused by variants affecting the gene represented in this entry. Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein. A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.
Topology
Extracellular: 33-143
Helical: 144-165
Cytoplasmic: 166-226
PTM
Phosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylated by LYN. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation.
Arginine methylation in the ITAM domain may interfere with the binding of SYK. It promotes signals leading to B-cell differentiation (By similarity).

Julamanee, J., Terakura, S., Umemura, K., Adachi, Y., Miyao, K., Okuno, S., ... & Kiyoi, H. (2021). Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Molecular Therapy.

Lenk, L., Carlet, M., Vogiatzi, F., Spory, L., Winterberg, D., Cousins, A., ... & Schewe, D. M. (2021). CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia. Communications biology, 4(1), 1-6.

Replicating, R. N. A. (2021). CD79A/CD40 endodomain enhances CAR-T persistence. Molecular Therapy, 29(9), 2627.

Berhili, A., Bensalah, M., ElMalki, J., Elyagoubi, A., & Seddik, R. (2021). Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report. Journal of Medical Case Reports, 15(1), 1-6.

Mangogna, A., Cox, M. C., Ruco, L., Lopez, G., Belmonte, B., & Di Napoli, A. (2020). Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-Cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a: a case report and review of the literature. Diagnostics, 10(6), 341.

Langereis, J. D., Henriet, S. S., Kuipers, S., Weemaes, C. M., van der Burg, M., de Jonge, M. I., & van der Flier, M. (2018). IgM augments complement bactericidal activity with serum from a patient with a novel CD79a mutation. Journal of clinical immunology, 38(2), 185-192.

Li, H., Li, Y., Zhang, X., Wang, Y., Zhang, W., Wu, X., & Wang, Z. (2017). Molecular characterization of the CD79a and CD79b and its role against Aeromonas hydrophila infection in Chinese sucker (Myxocyprinus asiaticus). Fish physiology and biochemistry, 43(6), 1571-1585.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human CD79A ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.